[1]邵秋静,冀紫阳,董　娇,等.外周血中微RNA-16和微RNA-124表达水平对抑郁症患者治疗效果的影响[J].新乡医学院学报,2022,39(4):318-322.[doi:10.7683/xxyxyxb.2022.04.004]
　SHAO Qiujing,JI Ziyang,DONG Jiao,et al.Effect of microRNA-16 and microRNA-124 in peripheral blood on clinical efficacy in patients with depression[J].Journal of Xinxiang Medical University,2022,39(4):318-322.[doi:10.7683/xxyxyxb.2022.04.004]
点击复制

外周血中微RNA-16和微RNA-124表达水平对抑郁症患者治疗效果的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年4
页码:
318-322
栏目:
临床研究
出版日期:
2022-04-05

文章信息/Info

Title:
Effect of microRNA-16 and microRNA-124 in peripheral blood on clinical efficacy in patients with depression
作者:
邵秋静; 冀紫阳; 董　娇; 王长虹
（新乡医学院第二附属医院精神科，河南　新乡　453002）
Author(s):
SHAO Qiujing; JI Ziyang; DONG Jiao; WANG Changhong
(Department of Psychiatry,the Second Affiliated Hospital of Xinxiang Medical University,Xinxiang 453002,Henan Province,China)
关键词:
抑郁症; 微RNA-16; 微RNA-124; 临床疗效
Keywords:
depression; microRNA-16; microRNA-124; clinical efficacy
分类号:
R749
DOI:
10.7683/xxyxyxb.2022.04.004
文献标志码:
A
摘要:
目的　探讨外周血中微RNA（miR）-16、miR-124表达水平对抑郁症患者治疗效果的影响。方法　选择2020年5月至2021年3月新乡医学院第二附属医院收治的60例抑郁症患者为研究对象。患者均接受米氮平片口服治疗，起始剂量为15 mg·d-1，服用2周后增加至30 mg·d-1，并维持此剂量服用；若服用2周后治疗效果不明显，可将米氮平片增加至45 mg·d-1，或调整为联合口服艾司西酞普兰，艾司西酞普兰起始剂量为每次10 mg·d-1；治疗周期为3个月。治疗3个月后，采用汉密尔顿焦虑量表（HAMA）、汉密尔顿抑郁量表（HAMD）评估所有患者临床疗效，并根据临床疗效将患者分为疗效不佳组（n=19）和疗效良好组（n=41）。治疗前，采集患者空腹静脉血3 mL，采用实时荧光聚合酶链式反应法检测患者外周血中miR-16、miR-124相对表达量。采用logistic回归分析外周血中miR-16、miR-124表达与抑郁症患者临床疗效的关系。绘制受试者工作曲线，并计算曲线下面积（AUC），分析外周血中miR-16、miR-124表达预测抑郁症患者临床疗效的价值。结果　疗效良好组患者外周血中miR-16相对表达量显著高于疗效不佳组，miR-124相对表达量显著低于疗效不佳组（P<0.05）。Logistic回归分析结果显示，miR-16是抑郁症患者临床疗效的保护因子（OR<1，P<0.05），miR-124是抑郁症患者临床疗效的危险因子（OR>1，P<0.05）。抑郁症患者外周血中miR-16、miR-124相对表达量单独及联合检测预测抑郁症患者临床疗效的AUC分别为0.843、0.849、0.944。外周血中miR-16和miR-124相对表达量单独及联合检测预测抑郁症患者临床疗效的AUC、敏感度比较差异无统计学意义（P>0.05）。miR-16、miR-124相对表达量联合检测预测抑郁症患者临床疗效的特异度显著高于miR-16相对表达量单独检测，显著低于miR-124相对表达量单独检测（P<0.05）。结论　抑郁症患者接受艾司西酞普兰、米氮平治疗的临床疗效欠佳可能受外周血中miR-16水平降低、miR-124水平升高影响，miR-16、miR-124表达水平联合检测预测抑郁症患者临床疗效不佳风险具有较高价值。
Abstract:
Objective　To investigate the effect of microRNA (miR)-16 and miR-124 expressions in peripheral blood on clinical efficacy in patients with depression.Methods　A total of 60 depression patients admitted to the Second Affiliated Hospital of Xinxiang Medical University from May 2020 to March 2021 were selected as the research subjects.All patients received oral mirtazapine tablet,the initial dose was 15 mg·d-1,which was increased to 30 mg·d-1 after two weeks of taking,and the dose was maintained;if the treatment effect was not obvious after two weeks of taking,mirtazapine tablet could be increased to 45 mg·d-1,or adjusted to be combined with oral escitalopram,the starting dose of escitalopram was 10 mg·d-1;the treatment period was three months.After three months of treatment,Hamilton anxiety scale (HAMA) and Hamilton depression scale (HAMD) were used to evaluate the clinical efficacy of all patients,and patients were divided into poor efficacy group (n=19) and good efficacy group (n=41) according to clinical efficacy.Before treatment,3 mL of fasting venous blood was collected from patients,and the relative expression levels of miR-16 and miR-124 in peripheral blood of patients were detected by real-time fluorescence polymerase chain reaction method.The relationship between the expression of miR-16 and miR-124 in peripheral blood and the clinical efficacy of patients with depression was analyzed by logistic regression.The value of the miR-16 and miR-124 expression in peripheral blood in predicting clinical efficacy in patients in the depression was analyzed by receiver operator characteristic,and the area under curve (AUC) was calculated.Results　The relative expression level of miR-16 in peripheral blood of patients in the good efficacy group was significantly higher than that in the poor efficacy group,and the relative expression level of miR-124 was significantly lower than that in the poor efficacy group (P<0.05).Logistic regression analysis showed that miR-16 was the protective factor for clinical efficacy in patients with depression (OR<1,P<0.05),and miR-124 was the risk factor for clinical efficacy in patients with depression (OR>1,P<0.05).The AUC of miR-16 and miR-124 levels in peripheral blood alone and in combination predicting the risk of poor clinical efficacy in patients with depression was 0.843,0.849,and 0.944,respectively.There was no significant difference in the AUC and sensitivity of the relative expressions of miR-16 and miR-124 in peripheral blood alone and in combinationfor predicting the clinical efficacy of depression patients (P>0.05). The specificity of the combined detection of the relative expression of miR-16 and miR-124 in predicting clinical efficacy in patients with depression was significantly higher than that of miR-16 alone,but significantly lower than that of miR-124 alone (P<0.05). Conclusion　The poor clinical efficacy of escitalopram and mirtazapine may be affected by the decrease in the level of miR-16 and the increase in the level of miR-124 in peripheral blood of patients with depression.The combined detection of miR-16 and miR-124 levels has high value in predicting the risk of poor clinical efficacy in patients with depression.

参考文献/References:

［1］　HU S C,CHEN G S,TU H P.Epidemiology of depression in patients with psoriasis:a nationwide population-based cross-sectional study［J］.Acta Derm Venereol,2019,99(6):530-538.
［2］　姚静，庞剑月，何瑾，等.反复发作抑郁症与5-羟色胺1A和5-羟色胺2A受体基因多态性的关联性研究［J］.中国神经精神疾病杂志,2020,46(1):13-18.
YAO J，PANG J Y,HE J,et al.A study on the association of recurrent major depressive disorder with polymorphisms of 5-hydroxytryptamine 1A receptor and 5-hydroxytryptamine 2A receptor gene［J］.J Nervment Dis,2020,46(1):13-18.
［3］　XU J H,JIANG P.Efficacy of escitalopram oxalate for patients with post-stroke depression［J］.Medicine (Baltimore),2018,97(14):e0219.
［4］　AKAMA F,MIKAMI K,WATANABE N,et al.Efficacy of mirtazapine on irritable bowel syndrome with anxiety and depression:a case study［J］.J Nippon Med Sch,2018,85(6):330-333.
［5］　王西田，王淑红，张陕宁，等.检测炎性因子(IL-6、TNF-α)、皮质醇及5-羟色胺(5-HT)对临床评价抑郁症患者病情发展及预后的作用［J］.国际精神病学杂志，2018，45(6):1032-1034.
WANG X T，WANG S H，ZHANG S N,et al.Objective to investigate the role of inflammatory factors (IL-6,TNF-a),cortisol and 5-serotonin (5-HT) in the clinical evaluation of the development and prognosis of patients with depression［J］.J Intl Psychiatry,2018，45(6):1032-1034.
［6］　SI Y,SONG Z,SUN X,et al.microRNA and mRNA profiles in nucleus accumbens underlying depression versus resilience in response to chronic stress［J］.Am J Med Genet B Neuropsychiatr Genet,2018,177(6):563-579.
［7］　SONG M F，DONG J Z，WANG Y W，et al.CSF miR-16 is decreased in major depression patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter system［J］.J Affect Disord,2015,178(1):25-31.
［8］　田涛，段芙蓉，戴立磊，等.抑郁症患者BDNF、IL-6及miR-124的表达与疾病严重程度关系研究［J］.精神医学杂志,2019,32(6):454-457.
TIAN T,DUAN F R,DAI L L,et al.Study on the relationship between the expression of BDNF,IL-6 and miR-124 and disease severity in patients with depression［J］.Psychiatr J,2019,32 (6):454-457.
［9］　SPIJKER J,CLAES S.Stemmingsstoornissen in de DSM-5.［J］.Tijdschr Psychiatr,2014,56(3):173-176.
［10］　王纯，楚艳民，张亚林，等.汉密尔顿焦虑量表的因素结构研究［J］.临床精神医学杂志，2011，21(5):299-301.
WANG C,CHU Y M,ZHANG Y L,et al.Study on factor structure of Hamilton anxiety scale［J］.J Clin Psychiatr,2011,21 (5):299-301.
［11］　PARK S C,J ANG E Y,KIM J M,et al.Clinical validation of the psychotic depression assessment scale,hamilton depression rating scale-6,and brief psychiatric rating scale-5:results from the clinical research center for depression study［J］.Psychiatry Invest,2017,14(5):568-576.
［12］　陈绘景，马子龙，宋晋.抑郁症患者家庭功能及其与临床预后的关系［J］.中南大学学报(医学版),2017,42(7):843-847.
CHEN H J,MA Z L,SONG J.Family function and its relationship with clinical prognosis in patients with major depressive disorder［J］.J Cent Southuniv(Medical Science),2017，42(7):843-847.
［13］　RIHMER Z,RIHMER A.Depression and suicide - the role of underlying bipolarity［J］.Psychiatr Hung,2019,34(4):359-368.
［14］　李静，李克建.老年脑卒中抑郁患者血清中miR-26b，miR-1水平与预后的关系［J］.中国医师杂志,2020,22(11):1707-1711.
LI J,LI K J.The relationships between levels of serum microRNA-26b and microRNA-1 and prognosis in elderly patients with stroke depression［J］.J Chin Phy,2020,22(11):1707-1711.
［15］　SHEN M,SONG Z,WANG J H.MicroRNA and mRNA profiles in the amygdala are associated with stress-induced depression and resilience in juvenile mice［J］.Psychopharmacology (Berl),2019,236(7):2119-2142.
［16］　QI B,FIORI L M,GUSTAVO T,et al.Machine learning analysis of blood microRNA data in major depression:a case-control study for biomarker discovery［J］.Int J Neuropsychopharmacol,2020,23(8):505-510.
［17］　翟天柱，沈宗霖，许秀峰.5-羟色胺1A受体及其基因rs6295位点多态性与抑郁症的研究进展［J］.医学综述,2018,24(4):631-635.
ZHAI T Z,SHEN Z L,XU X F.Research progress of 5-hydroxytryptamine 1a receptor and its gene rs6295 polymorphism and depression［J］.Med Recap,2018,24(4):631-635.
［18］　LIU Q,ZHOU J.Effect of miR-16 on behaviors of depression model mice through regulating NF-κB pathway［J］.Minerva Endocrinol,2019,44(4):397-399.
［19］　李桂萍，宋明芬，李静，等.降低脑脊液miR-16的水平对大鼠抑郁样行为的影响［J］.中国病理生理杂志,2020,36(10):1875-1880.
LI G P,SONG M F,LI J,et al.Effects of decreasing miR-16 in cerebrospinal fluid on depression-like behaviors in rats［J］.Chin J Pathophysiol,2020,36(10):1875-1880.
［20］　GU Z,PAN J,CHEN L.miR-124 suppression in the prefrontal cortex reduces depression-like behavior in mice［J］.Biosci Rep,2019,39(9):BSR20190186.
［21］　WANG S S,MU R H,LI C F,et al.microRNA-124 targets glucocorticoid receptor and is involved in depression-like behaviors［J］.Prog Neuropsychopharmacol Biol Psychiatry,2017,79(Pt B):417-425.
［22］　袁梅菊，毕雪飞.首发抑郁症患者外周血microRNA-124的变化及临床意义［J］.精神医学杂志,2018,31(1):27-29.
YUAN M J,BI X F.Changes and clinical significance of microRNA-124 in peripheral blood of patients with first-episode depression［J］.J Psychiatry,2018,31(1):27-29.
［23］　冯倩，汤臻，周华，等.抑郁症患者治疗前血浆microRNA-16、microRNA-195表达水平研究［J］.中国心理卫生杂志，2016，30(10):758-760.
FENG Q,TANG Z,ZHOU H,et al.Study on the expression levels of plasma microRNA-16 and microRNA-195 in patients with depression before treatment［J］.Chin J Ment Health,2016,30 (10):758-760.
［24］　罗焕，王平，夏川，等.慢性不可预知温和应激小鼠脑内和血清miR-124表达的研究［J］.湖南师范大学学报(医学版),2018,15(3):10-14.
LUO H,WANG P,XIA C,et al.miR-124 expression in the brain and serum of chronic unpredictable mild stress mice［J］.J Hunan Normal Univ(Medical Science),2018，15(3):10-14.

相似文献/References:

[1]陈佐明,张建宏,张秀明,等.单次发作抑郁症过氧化脂质及谷胱甘肽过氧化物酶检测的意义[J].新乡医学院学报,1995,12(02):153.
[2]梁炜,陈佐明,张留莎.氟西汀与丙咪嗪治疗抑郁症的对照研究[J].新乡医学院学报,2000,17(02):102.
[3]孟 焱,杜 江,王 萍.舍曲林与阿米替林治疗老年期抑郁症的双盲比较[J].新乡医学院学报,2002,19(03):181.
[4]孟 焱,杜 江,王 萍.舍曲林与阿米替林治疗老年期抑郁症的双盲比较[J].新乡医学院学报,2002,19(03):181.
[5]孟庆莉,谭 军.清热解躁汤治疗脑血管病后抑郁症31例[J].新乡医学院学报,2002,19(05):432.
[6]邹韶红,党海红,黄国平.抑郁症81例应对方式的性别差异 [J].新乡医学院学报,2004,21(01):000.
[7]张顺英,李臻,胡萌.家庭访视及护理指导对抑郁症患者综合依从性和疗效的影响[J].新乡医学院学报,2009,26(04):426.
[8]王长虹,李晏,谢春朋,等.抑郁症的神经内分泌研究进展[J].新乡医学院学报,2011,28(06):000.
[9]张小毅,李生莹,何益群,等.氟西汀对慢性温和应激抑郁模型大鼠海马神经干细胞的影响[J].新乡医学院学报,2012,29(11):818.
[10]赵利芹,李　晏,邵秋静,等.丰富环境对抑郁大鼠行为学及海马组织中丝裂原活化蛋白激酶磷酸酶-1表达的影响[J].新乡医学院学报,2017,34(9):798.[doi:10.7683/xxyxyxb.2017.09.005]
　ZHAO Li-qin,LI Yan,SHAO Qiu-jing,et al.Effects of enriched environment on behavior and expression of mitogen-activated protein kinase phosphatase-1 in hippocampus of depression rats[J].Journal of Xinxiang Medical University,2017,34(4):798.[doi:10.7683/xxyxyxb.2017.09.005]

更新日期/Last Update: 2022-04-05